Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor versus clopidogrel in Japanese and Asian patients with stable coronary artery disease
jRCT2080221135Phase 2
- Sponsor
- AstraZeneca
- Start
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ticagrelor in coronary arteriosclerosis (2 arms), sponsored by AstraZeneca. Primary endpoints: Pharmacokinetic profile of ticagrelor and Pharmacodynamic effect on platelet aggregation.
02
Drugs
ticagrelor
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on jRCT2080221135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221135.